Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Core Insights - Syndax Pharmaceuticals will host an in-person investor event on December 8, 2025, at 7:00 a.m. ET during the ASH Annual Meeting to discuss data updates from its Revuforj and Niktimvo programs [1] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, with key products including Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3] - The company is committed to advancing its pipeline and is conducting several clinical trials across various treatment stages [3]